Influenza pneumonia among adolescents and adults: a concurrent comparison between influenza A (H1N1) pdm09 and A (H3N2) in the post-pandemic period

Shu Qiao Yang1*, Jiu Xin Qu1*, Chen Wang2,3,4,5, Xiao Min Yu1, Ying Mei Liu1 and Bin Cao1

1 Department of Infectious Diseases and Clinical Microbiology, Beijing Chao-Yang Hospital, Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing, China
2 Institute of Respiratory Medicine, Beijing Hospital, Ministry of Heath, Beijing, China
3 Department of Respiratory Medicine, Capital Medical University, Beijing, China
4 Beijing Institute of Respiratory Medicine, Beijing, China
5 Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, China

Abstract

Introduction: Comparisons of the characteristics between the influenza A (H1N1) pdm09 and common seasonal influenza are important for both clinical management and epidemiological studies. However, the differences between pandemic and seasonal influenza during the post-pandemic period are poorly understood.

Objectives: The aim of our research was to investigate clinical and immune response differences between patients with influenza A (H1N1) pdm09 pneumonia and seasonal influenza A (H3N2) pneumonia in the post-pandemic period.

Methods: During the first flu season in post-pandemic period, patients from Beijing Network for Adult Community-Acquired Pneumonia present A (H1N1) pdm09 or A (H3N2) influenza were compared concurrently in the aspects of clinical characteristics and inflammatory profile in acute phase.

Result: Patients with A (H1N1) pdm09 influenza pneumonia showed a close mean age to A (H3N2) pneumonia (51 ± 20 vs 53 ± 16, mean ± standard deviation, years) but tended to have more underlying diseases (32.8% vs 10%, $P = 0.036$). Although clinical characteristics were similar, no statistical difference were found in pneumonia severity index (PSI) score or intensive care unit admission rate or mortality, patients in A (H1N1) pdm09 cohort present higher levels of aspartate aminotransferase, lactase dehydrogenase ($P = 0.006$, 0.018, respectively) in blood and also longer duration of fever than A (H3N2) cohort. Levels of interleukin (IL)-10 and IL-12 (p70) were higher in A (H1N1) pdm09 cohort ($P = 0.031$, 0.047, respectively).

Conclusions: During the first post-pandemic flu season, patients with the A (H1N1) pdm09 pneumonia showed similar clinical characteristics but slightly higher disease severity and stronger systemic inflammatory response than A (H3N2) pneumonia.

Please cite this paper as: Yang SQ, Qu JX, Wang C, Yu XM, Liu YM and Cao B. Influenza pneumonia among adolescents and adults: a concurrent comparison between influenza A (H1N1) pdm09 and A (H3N2) in the post pandemic period. Clin Respir J 2014; 8: 185–191.
Introduction

In 2009, a novel influenza A (H1N1) pdm09 caused outbreaks of respiratory illness in southern America and reached nearly every country in the world within several weeks (1). As of August 2010, more than 214 countries had reported laboratory-confirmed cases resulting a total number over 18 449 death (2). Early published data during pandemic have shown that infection and serious illnesses occurred mostly in children and young adults, which differed significantly from seasonal influenza (3, 4).

During pandemic in 2009, Kelvin KW To and coauthors demonstrated that pandemic A (H1N1) patients were younger, less likely to have lower respiratory tract symptoms, more likely to be obese or pregnant (5) compared with seasonal influenza. Nelson Lee et al. also proved that hospitalized patients with A (H1N1) pdm09 influenza were younger than those with seasonal influenza and had higher rates of extrapulmonary complications and intensive care unit (ICU) admission and/or death (6). Susanna Esposito et al. (7) showed symptom severity and the risk of serious outcomes (admission to ICU or death) were similar in children because of pandemic H1N1 or seasonal A (H3N2).

But the main limitation of these studies is that comparison was made during pandemic, as it is easily understood when a new subtype of influenza virus was introduced into the community. When A (H1N1) pdm09 virus has been circulating and became an endemic causative respiratory pathogen during post-pandemic, it is unclear whether the A (H1N1) pdm09 has some difference from pre-existing influenza A (H3N2).

During the immediate post-pandemic period, a surveillance network (Beijing Network for Adult Community-Acquired Pneumonia, BNACAP), comprising 12 general hospitals in Beijing, was established to survey community-acquired pneumonia (CAP) cases in Beijing district. Such survey offered a unique opportunity to study the behavior of A (H1N1) pdm09 influenza during the immediate post-pandemic phase and perform a concurrent comparison between A (H1N1) pdm09 influenza pneumonia and seasonal influenza A (H3N2) pneumonia. Cytokine dysregulation may contribute to lung pathology and severity of influenza A virus infection (8). Another novelty of this study is that we also compared the immune response between the two kinds of pneumonia.

Materials and methods

Study population

During November 2010 and April 2011, the first flu season in post-pandemic period, adolescent and adult patients (aged 14 years or above) with chest radiograph confirmed CAP from 12 general hospitals were consecutively enrolled in BNACAP. Patients were excluded if they met any of the following items: time before enrollment since disease onset >7 days, immunocompromised patients with human immunodeficiency virus infection, neutropenia, receiving immunosuppressive chemotherapy, pregnant or breastfeeding women, and known or suspected active tuberculosis.

Data collection and microbiology diagnosis

Epidemiological data, symptoms and signs, laboratory findings on admission, clinical course, treatment, and outcomes were recorded. The pneumonia severity index (PSI) was used to assess the severity of illness (9).

Throat swab specimens, sputum, serum and urine were collected on admission. Throat swabs were performed with 2-mL transport broth medium (CM403, OXOID, Basingstoke, Hampshire, UK) and stored at –80°C until transportation on ice to the central laboratory in Beijing Chao-Yang Hospital within 2 weeks. Multiplex polymerase chain reaction (PCR) assay (RV15 ACE Detection, Seegene, Inc., Seoul, Korea) were used to detect influenza virus and other 14 kinds of common respiratory pathogens. Samples confirmed with influenza virus infected were subsequently discriminated for subtypes by real-time, reverse transcriptase (RT) PCR assay [Diagnostic Kit for seasonal influenza A subtype H3 and H1 virus RNA; Diagnostic Kit for pandemic influenza A (H1N1) virus RNA, Kinghawk, Inc., Peking, China]. Blood cultures were performed for patients presenting with chills and shivering. If pleural fluid and sputum samples were available, Gram stain and quantitative culture were performed. The sputum sample was determined to be adequate if >25 polymorphonuclear cells and <10 epithelial cells were counted per high power field. Urinary antigen tests for *Legionella pneumophila* and *Streptococcus pneumoniae* (BinaxNow® *S. pneumoniae* and BinaxNow Legionella, Scarborough, ME, USA) were also performed.

Cases of A (H1N1) pdm09 virus or seasonal H3N2 virus infection were defined when RT-PCR assay present positive results. Bacteria coinfection was considered if etiology were detected by culture or Gram stain, or urinary antigen tests.
Cytokines and chemokines quantification

Cytokine and chemokine levels were evaluated by using the multiplex Biorad 27plex assay (Hercules, CA, USA) in serum of acute phase, if available, for healthy volunteers and patients with pandemic influenza A (H1N1) virus or seasonal influenza virus infection. The kit was customized to quantify 20 kinds of cytokines and chemokines in serum, including interleukin (IL)-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, eotaxin, interferon (IFN)-r, IFN gamma-induced protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), regulated on activation, normal T-cell expressed and secreted (RANTES), and tumor necrosis factor (TNF)-α.

Statistical analysis

SPSS 17.0 was utilized to perform data analysis. Two-tailed independent samples t-test or Mann–Whitney U-test (on condition of non-normal distributions) was conducted to compare continuous variables between two groups. As for the categorical data, univariate analysis was carried out using the chi-square test or Fisher’s exact test. Measurement data are displayed as mean ± standard deviation (SD), or as median (interquartile rank) when data were not normally distributed. Numeration data are presented in numbers (%). Significance was fixed at P value <0.05.

Results

Epidemiological data

There were 92 patients presenting influenza A infection, 62 with A (H1N1) pdm09 influenza and 34 with seasonal influenza (H3N2), among them, four were coinfected with both of the two kinds of virus and thus were excluded. Acute phase serum was successfully collected from 55 cases [31 A (H1N1) pdm09 influenza and 24 influenza A (H3N2)] and 14 healthy volunteers for examination of the cytokine and chemokine profile.

Clinical characteristics and clinical outcome comparison

Comparison between clinical characteristic of patients with A (H1N1) pdm09 influenza pneumonia and seasonal influenza (H3N2) pneumonia are detailed in Table 1.

Cytokine and chemokine data

Increased serum concentrations of inflammatory cytokines and chemokines, including IL-1ra, IL-4, IL-6, IL-7, IL-8, RANTES and eotaxin, were observed in both groups when compared with normal control group (P <0.05). Moreover, statistically significant higher levels of IL-10 and IL-12 (p70) were found in A (H1N1) pdm09 group in comparison with seasonal influenza (H3N2) group (P = 0.031, 0.047, respectively). Cytokine and chemokine profile were shown in Fig. 1.

Discussion

Data from this study present similar clinical characteristics but still a slightly higher disease severity in patients between A (H1N1) pdm09 influenza pneumonia during post-pandemic period, when concurrently compared with seasonal influenza (H3N2) pneumonia.
### Table 1. Clinical characteristics of patients with A (H1N1) pdm09 influenza pneumonia and seasonal influenza (H3N2) pneumonia

|                        | Total (N = 88) | A (H1N1) pdm09 (n = 58) | A (H3N2) (n = 30) | P value |
|------------------------|---------------|-------------------------|-------------------|---------|
| **Basic statistics**   |               |                         |                   |         |
| Male                   | 48 (54.5%)    | 34 (58.6%)              | 14 (46.7%)        | 0.29    |
| Age (years)            | 52 ± 19       |                         | 53 ± 16           | 0.70    |
| **Underlying diseases**| 22 (25%)      | 19 (32.8%)              | 3 (10%)           | 0.019   |
| COPD                   | 9 (10.2%)     | 7 (12.1%)               | 2 (6.7%)          | 0.67    |
| Diabetes               | 6 (6.8%)      | 6 (10.3%)               | 0                 | –       |
| Coronary heart diseases| 7 (8.0%)      | 5 (8.6%)                | 2 (6.7%)          | 1.0     |
| Cerebrovascular diseases| 5 (5.7%)     |                         | 5 (8.6%)          |         |
| Chronic heart diseases  | 1 (1.1%)      | 1 (1.7%)                | 0                 | –       |
| Chronic renal diseases  | 2 (3.2%)      | 2 (3.4%)                | 0                 | –       |
| Cirrhosis              | 2 (2.3%)      |                         | 2 (3.4%)          |         |
| **Smoking history**    | 24 (27.3%)    | 16 (27.6%)              | 8 (26.7%)         | 1.0     |
| **Influenza vaccination within 1 year** | 7 (8.0%) | 7 (12.1%) | 0             | –       |
| Streptococcus pneumoniae vaccination within 1 year | 2 (2.3%) | 2 (3.4%) | 0             | –       |
| **Antibiotics before enrollment** | 53 (60.2%) | 32 (55.2%) | 21 (70.0%) | 0.25 |
| **Symptoms and signs on admission** |               |                         |                   |         |
| Fever                  | 85 (96.6%)    | 57 (98.3%)              | 28 (93.3%)        | 0.55    |
| Tmax (°C)              | 38.9 (38.8–39.1) | 38.9 (38.8–39.1) | 38.9 (38.6–39.3) | 0.65 |
| Cough                  | 85 (96.6%)    | 56 (96.6%)              | 29 (96.7%)        | 1.0     |
| Expectoration          | 85 (96.6%)    | 56 (96.6%)              | 29 (96.7%)        | 1.0     |
| White sputum           | 24 (27.3%)    | 16 (27.6%)              | 8 (26.7%)         | 1.0     |
| Yellow sputum          | 30 (42.3%)    | 20 (34.5%)              | 10 (34.5%)        | 0.81    |
| Bloody sputum          | 4 (5.5%)      | 2 (3.4%)                | 2 (6.7%)          | 1.0     |
| Dyspnea                | 13 (14.3%)    | 9 (15.5%)               | 4 (13.3%)         | 0.06    |
| Chest pain             | 25 (28.4%)    | 17 (29.3%)              | 8 (26.7%)         | 1.0     |
| Nausea or vomiting     | 6 (6.8%)      | 3 (5.2%)                | 3 (10.0%)         | 0.69    |
| Headache or dizziness  | 11 (12.5%)    | 6 (10.3%)               | 5 (16.7%)         | 0.61    |
| Confusion              | 0             | 0                       | 0                 | –       |
| Respiratory rate (min) | 20 (19.7–21.1) | 20 (19.8–21.7) | 20 (19.1–20.3) | 0.25 |
| Systemic blood pressure (mmHg) | 72 (71.1–74.6) | 72 (71.1–74.6) | 72 (71.1–74.6) | 0.67 |
| **Laboratory findings on admission** |               |                         |                   |         |
| WBC (×10^9/L)          | 6.9 ± 2.9     | 7.3 ± 2.9               | 6.4 ± 2.7         | 0.16    |
| Lymphocytes (×10^9/L)  | 1.1 ± 0.5     | 1.1 ± 0.5               | 1.1 ± 0.5         | 0.74    |
| Hemoglobin (g/L)       | 133.6 ± 19.5  | 132.7 ± 22.3            | 135 ± 13.2        | 0.58    |
| Platelet (×10^9/L)     | 190.8 ± 70.2  | 189.9 ± 71.1            | 192.4 ± 68.8      | 0.87    |
| Abnormal ECG           | 20 (22.7%)    | 16 (27.6%)              | 4 (13.3%)         | 0.13    |
| ALT (U/L)              | 21 (22.1–31.1) | 22 (22.5–35.7) | 18 (17.9–26.3) | 0.39 |
| AST (U/L)              | 24.4 (25.2–33.8) | 27 (27.2–39.8) | 20 (19.5–25.0) | 0.006   |
| ALB (g/L)              | 37.1 ± 5.9    | 35.3 ± 5.9              | 40.3 ± 4.1        | <0.001  |
| LDH (U/L)              | 182.5 (187.3–219.6) | 201 (198.6–242.8) | 175 (154.6–189.5) | 0.018 |
| CK (U/L)               | 90 (105.4–172.9) | 89 (110.2–191.2) | 91 (55.1–180.9) | 0.32 |
| Cr (μmol/L)            | 71.1 ± 19.9   | 71.9 ± 19.5             | 71.6 ± 13.1       | 0.93    |
| ESR (mm/h)             | 14.6 (6.2–48.4) | 14.2 (6.0–50) | 15.4 (9.8–44.6) | 0.53 |
| Treatment and outcomes |               |                         |                   |         |
| Isolated               | 64 (72.7%)    | 47 (81.0%)              | 17 (56.7%)        | 0.015   |
| ICU admission          | 1 (1.2%)      | 1 (1.7%)                | 0                 | –       |
| Antiviral therapy      | 15 (17.0%)    | 15 (25.9%)              | 0/30              | –       |
| Antiviral within 48 h onset | 1 (1.1%) | 1 (1.7%) | 0 | – |
| Antibiotics after enrollment | 88 (100%) | 58 (100%) | 30 (100%) | – |
| Noninvasive ventilation| 4 (4.5%)      | 4 (6.9%)                | 0                 | –       |
| Invasive ventilation   | 1 (1.1%)      | 1 (1.7%)                | 0                 | –       |
| Vasoactive agents      | 2 (2.3%)      | 1 (1.7%)                | 1 (3.3%)          | 1.0     |
| Secondary bacterial infections | 9 (14.3%) | 3 (7.7%) | 6 (25.0%) | 0.13 |
| Complications          |               |                         |                   |         |
| ARDS                   | 2 (2.3%)      | 2 (3.4%)                | 0                 | –       |
| Severe sepsis          | 1 (1.1%)      | 1 (1.7%)                | 0                 | –       |
| Acute renal failure    | 0             | 0                       | 0                 | –       |

**Measurement data are displayed as mean ± standard deviation, or as median (interquartile rank) when data were not normally distributed, numeration data are presented in numbers (%). COPD, chronic obstructive pulmonary disease; PST, pneumonia severity index; WBC, white blood cell; Hb, hemoglobin; ECG, electrocardiogram; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, albumin; LDH, lactase dehydrogenase; CK, creatinine kinase; Cr, creatinine; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; PT, prothrombin time; ARDS, acute respiratory distress syndrome; PSI, pneumonia severity index. Bold values indicate statistical significance.**
As in the pandemic period, studies have reported a younger age and fewer comorbid conditions in adult patients with A (H1N1) pdm09 influenza than seasonal influenza, and this was supposed to result from a lack of cross-reactive antibody toward A (H1N1) pdm09 in the younger population (5, 6, 10). On the 10th of August, World Health Organization announced that 2009 pandemic had ‘largely run its course’, the A (H1N1) pdm09 influenza entered the post-pandemic period. Based on available evidence and experience from past pandemics, the virus was expected to take on the behavior of a seasonal influenza virus (11). In the post-pandemic phase, an upward shift in age distribution of patients infected with A (H1N1) pdm09 virus was reported (12–14). In our study, we also detected a close mean age between patients with A (H1N1) pdm09 influenza pneumonia and seasonal influenza (H3N2) pneumonia, considering the A (H1N1) pdm09 virus has already been reported to remain genetically stable with no increase in virulence since its origin (15); this upward shift in age distribution is probably due to a higher seropositivity against A (H1N1) pdm09 virus in young adult patients.

During the pandemic period, data from Lee et al. (6) indicated that patients with A (H1N1) pdm09 influenza have higher rates of extrapulmonary complications, and ICU admission and/or death than seasonal influenza. Riquelme et al. (16) conducted a comparison between A (H1N1) pdm09 influenza pneumonia and seasonal influenza (H3N2) pneumonia, rate of ICU admission and mechanical ventilation were found to be higher, and mortality was twice as high in the group of A (H1N1) pdm09 influenza. However, this study used historical data for comparison, thus potential biases may arise. In our study, although the mean ages were close, symptoms and signs were similar; the rate of ICU admission and death did not differ obviously; and significantly higher serum levels of both AST and LDH, higher rate of hospitalization, and longer duration of fever were found in influenza A (H1N1) pdm09 cohort. The elevation of AST and LDH in blood usually indicate the damage of muscle or organ, which, has been found to be higher in severe patients with A (H1N1) pdm09 virus infection than nonsevere patients (17).

Measurement of cytokines in plasma revealed elevated levels of IL-10 and IL-12 in A (H1N1) pdm09 compared with A/H3N2. IL-10 acts as a major immunomodulatory cytokine. It can inhibit antigen-presenting cells and macrophage function, suppress Th1 cytokine production, and impair T-cell responses (18). Increased production of IL-10 probably reflects a host response to dampen over-exuberant pulmonary inflammation and promote tissue repair (19). IL-12 appears to be important primarily in early activation of the immune response during primary influenza virus infection. IL-12 contributes to the inhibition of early virus replication but is not required for virus clearance. IL-12 also modestly contributes to the activation of cytotoxic T lymphocytes (20). Higher levels of IL-10 and IL-12 (p70) in A (H1N1) pdm09 group in comparison with H3N2 group may indicate a slightly stronger systemic inflammatory response.

The stronger systemic inflammatory response in A (H1N1) pdm09 was supported by animal model by Itoh et al. (19). They found that infection with A/Kawasaki/UTK-4/09 resulted in limited induction of pro-
inflammatory cytokines/chemokines in the lungs in marked contrast with infection with A (H1N1) pdm09.

But Österlund et al. (21) reported a poor pro-inflammatory cytokine gene expression in human monocyte-derived dendritic cells and macrophages infected with A (H1N1) pdm09. Woo et al. (22) also documented that no major cytokine storm, as in H5N1 infection, is associated with A (H1N1) pdm09 infection. Janina Geiler et al. (23) even demonstrated that pandemic H1N1/2009 increased IP-10, TNF-α, CXCL8 (interleukin 8 [IL-8]), macrophage inflammatory protein 1α and IL-6 expression to a lesser extent than H5N1/2004 or H3N2/2004.

The difference might be due to the sample types and viral load between these studies and ours. First, compared with animal or in vitro immunocytes infection model, our study is the only clinical trial. Even for clinical trials, the severity of illness or sera collection time after infection might also contribute the difference. Second, the apparent difference between these in vitro data reflects different viral loads used in these studies (22). The plasma levels of IP-10, MCP-1, IL-8, IL-6 and IL-10 correlated with pharyngeal H5N1 load (23).

There are several limitations of our study. First, a relatively small sample size may limit the statistical power. Second, only adolescent and adult patients were included; therefore, the findings cannot be generalized to the whole population. Third, the obvious higher proportions of patients with underlying diseases like chronic obstructive pulmonary disease in the pH 1N1 cohort may result in influenza A (H1N1) pdm09 infection more severe than H3N2 infection.

In conclusion, during the first post-pandemic flu season, patients with influenza A (H1N1) pdm09 pneumonia showed similar clinical characteristics but slightly higher disease severity and stronger systemic inflammatory response than seasonal influenza A (H3N2) pneumonia.

Acknowledgements

We acknowledge the support from the staff at hospitals that contributed to the establishment and work of BNAcap, including Beijing Haidian Hospital, Peking University People’s Hospital, Luhe Teaching Hospital of the Capital Medical University, Wangjing Hospital of China Academy of Chinese Medical Sciences, Peking Union Medical College Hospital, China-Japan Friendship Hospital, Beijing Friendship Hospital, Beijing Pinggu Hospital, Huairou the First Hospital and Air Force General Hospital, and YanTai Yu Huangding Hospital.

References

1. Ison MG, Lee N. Influenza 2010–2011: lessons from the 2009 pandemic. Cleve Clin J Med. 2010;77: 812–20.
2. World Health Organization. Global Alert and Response (GAR). Pandemic (H1N1) 2009 – Update 112 (revised 6 August 2010). Geneva, WHO, 2010. Available at: http://www.who.int/csr/don/2010_08_06/en/index.html (accessed August 2010).
3. Falagas ME, Koletsi PK, Baskouta E, Rafailidis PI, Dimopoulou G, Karageorgopoulou DE. Pandemic A (H1N1) 2009 influenza: review of the Southern Hemisphere experience. Epidemiol Infect. 2011;139: 27–40.
4. Sullivan SJ, Jacobson RM, Dowdle WR, Poland GA. 2009 H1N1 influenza. Mayo Clin Proc. 2010;85: 64–76.
5. To KK, Wong SS, Li IW, Hung IF, Tse H, Woo PC, Chan KH, Yuen KY. Concurrent comparison of epidemiology, clinical presentation and outcome between adult patients suffering from the pandemic influenza A (H1N1) 2009 virus and the seasonal influenza A virus infection. Postgrad Med J. 2010;86: 515–21.
6. Lee N, Chan PK, Lui GC, et al. Complications and outcomes of pandemic 2009 Influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? J Infect Dis. 2011;203: 1739–47.
7. Esposito S, Molteni CG, Daleno C, Tagliabue C, Picciolli I, Scala A, Pelucchi C, Fossali E, Principi N. Impact of pandemic A/H1N1/2009 influenza on children and their families: comparison with seasonal A/H1N1 and A/H3N2 influenza viruses. J Infect. 2011;63: 300–7.
8. Chan MCW, Cheung CY, Chui WH, Tsao SW, Nicholls JM, Chan YO, Chan RWY, Long HT, Poon LLM, Guan Y, Peiris JSM. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res. 2005;6: 135–47.
9. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336: 243–50.
10. Dalton CB, Cretikos MA, Durrheim DN, Seppelt IM, Rawlinson WD, Dwyer DE. Comparison of adult patients hospitalised with pandemic (H1N1) 2009 influenza and seasonal influenza during the ‘PROTECT’ phase of the pandemic response. Med J Aust. 2010;192: 357–8.
11. Eurosurveillance Editorial Team. World Health Organization declares post-pandemic phase. Euro Surveill. 2010;15(32): pii=19636.
12. Viasus D, Cordero E, Rodriguez-Baño J, et al. Changes in epidemiology, clinical features and severity of influenza A (H1N1) 2009 pneumonia in the first post-pandemic influenza season. Clin Microbiol Infect. 2012;18(3): E55–62.
13. Rahamat-Langendoen JC, Tutuhatunewa ED, Schölvinck EH, Hak E, Koopmans M, Niesters HG, Riezebos-Brilman
A. Influenza in the immediate post-pandemic era: a comparison with seasonal and pandemic influenza in hospitalized patients. J Clin Virol. 2012;54(2): 135–40.

14. Chuang JH, Huang AS, Huang WT, Liu MT, Chou JH, Chang FY, Chiu WT. Nationwide surveillance of influenza during the pandemic (2009–10) and post-pandemic (2010–11) periods in Taiwan. PLoS One. 2012;7(4): e36120.

15. Ellis J, Galiano M, Pebody R, et al. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11. Euro Surveill. 2011;16(1): pii=19760.

16. Riquelme R, Torres A, Rioseco ML, et al. Influenza pneumonia: a comparison between seasonal influenza virus and the H1N1 pandemic. Eur Respir J. 2011;38: 106–11.

17. Cho WH, Kim YS, Jeon DS, et al. Outcome of pandemic H1N1 pneumonia: clinical and radiological findings for severity assessment. Korean J Intern Med. 2011;26: 160–7.

18. Yu X, Zhang X, Zhao B, Wang J, Zhu Z, Teng Z, Shao J, Shen J, Gao Y, Yuan Z, Wu F. Intensive cytokine induction in pandemic H1N1 Influenza virus infection accompanied by robust production of IL-10 and IL-6. PLoS ONE. 2011;6(12): e28680.

19. Itoh Y, Shinya K, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009;460: 1021–5.

20. Monteiro JM, Harvey C, Trinchieri G. Role of interleukin-12 in primary influenza virus infection. J Virol. 1998;72: 4825–31.

21. Österlund P, Pirhonen J, Ilkonen N, et al. Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons. J Virol. 2010;84(3): 1414–22.

22. Woo PCY, Tung ETK, Chan K-H, Lau CCY, Lau SKP, Yuen K-Y. Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: implications for treatment strategies. J Infect Dis. 2010;201: 346–53.

23. Geiler J, Michaelis M, Sithisarn P, Cinatl J Jr. Comparison of pro-inflammatory cytokine expression and cellular signal transduction in human macrophages infected with different influenza A viruses. Med Microbiol Immunol. 2011;200: 53–60.